Current Trends in Research

  • Michael R. Hayden
Chapter

Abstract

The number of articles on Huntington’s chorea in the scientific literature has increased dramatically over the past 10 years. In 1970 there were 27 citations on Huntington’s chorea in Index Medicus and this had trebled to 83 in 1979. Another expression of the recent upsurge in interest was the establishment of the Commission for the Control of Huntington’s Disease and its Consequences in the USA in 1977, whose purpose was to report on the state of research and management in this disorder. In October 1977 their report was tabled before the Congress and President of America and as a result of their recommendations there has been added financial support for research on Huntington’s chorea in America and other parts of the world.

Keywords

Kainic Acid Predictive Test Abnormal Gene Affected Person Antineuronal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anden NE (1974) Inhibition of the turnover of the brain dopamine after treatment with gamma-aminobutyrate: 2-oxyglutarate transamine inhibitor amino-oxyacetic acid. Arch Pharmacol 283: 419–424Google Scholar
  2. Arlett CF, Muriel WJ (1979) Radiosensitivity in Huntington’s chorea cell strains: a possible pre-clinical diagnosis. Heredity 42: 276Google Scholar
  3. Arlett CF (1980) Presymptomatic diagnosis of Huntington’s disease? Lancet I: 540Google Scholar
  4. Arregui A, Bennett JP, Bird ED, Tamumura HI, Iverson LL, Snyder SH (1977) Huntington’s chorea: selective depletion of angiotensin convertng enzyme in the corpus striatum. Ann Neurol 2: 294–298PubMedCrossRefGoogle Scholar
  5. Arregui A, Iversen LL, Spokes EG, Emson PC (1979) Alterations in postmortem brain angiotensin-converting enzyme activity and some neuropeptides in Huntington’s disease. In: Chase TN, Wexler NS,Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 517–526Google Scholar
  6. Auerbach P (1980) Immunohistochemical study of foci of recent cell death in Huntington’s disease. Canad J Neurol Sci 7 (2): 87 - S8Google Scholar
  7. Barkley DS, Hardiwidjaja S, Menkes JH (1977) Abnormalities in growth of skin fibroblasts of patients withHuntington’s disease. Ann Neurol 1: 428430Google Scholar
  8. Barkley DS, Hardiwidjaja S, Tourtellotte W, Menkes JH (1978) Cellular immune responses in Huntington’s disease. Neurology 28: 32–35PubMedGoogle Scholar
  9. Baro F (1973) A neuropsychological approach to early detection of Huntington’s chorea. In: Barbeau A, Chase TN, Paulson GW (eds) Huntington’s chorea, 1872–1972. Raven Press, New York, pp 329–338Google Scholar
  10. Bernheimer H, Hornykiewicz O (1973) Brain amines in Huntington’s chorea. In: Barbeau A, Chase TN,Paulson GW (eds) Huntington’s chorea, 1872–1972.Raven Press, New York, pp 525–553Google Scholar
  11. Bernheimer H, Sperk G, Price KS, Hornykiewicz O (1979) Brain gangliosides in Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 463–471Google Scholar
  12. Beverstock G (1979) Communication to Eighth International Workshop on Huntington’s Chorea, Oxford, EnglandGoogle Scholar
  13. Bird ED, Iversen LL (1974) Post mortem measurements of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain 97: 457–472PubMedCrossRefGoogle Scholar
  14. Bird ED, Iversen LL (1976) Neurochemical findings in Huntington’s chorea. In: Youdim MBH, Lovenberg W, Sharman DF, Lagnado JR (eds) Essays in neurochemistry and neuropharmacology. Wiley, New York, pp 177–193Google Scholar
  15. Bird ED, Caro AJ, Pilling JB (1973) A sex-related factor in the inheritance of Huntington’s chorea. Ann Hum Genet 37: 255–259CrossRefGoogle Scholar
  16. Bird TD (1976) Normal glutamic acid decarboxylase activity in kidney tissue from patients with Huntington’s disease. J Neurochem 27: 1555–1557PubMedCrossRefGoogle Scholar
  17. Brown WT, Ambruster J, Darlington GJ (1979) Two-dimensional analysis of radiolabeled proteins in cultured Huntington’s disease fibroblasts. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 361–370Google Scholar
  18. Butterfield DA, Oeswein JQ, Markesbery WR (1977) Electron spin resonance study of membrane protein alteration in erythrocytes in Huntington’s disease. Nature 267: 453–455PubMedCrossRefGoogle Scholar
  19. Butterfield DA, Oeswein JQ, Prunty MJ, Hisle KC, Markesbery WR (1978a) Increased sodium plus potassium adenosine-triphosphatase activity in erythrocyte membranes in Huntington’s disease. Ann Neurol 4: 60–62PubMedCrossRefGoogle Scholar
  20. Butterfield DA, Prunty MJ, Markesbery WR (1978b) Electron spin resonance haematological and deformability studies of erythrocytes from patients with Huntington’s disease. Biochem Biophys Acta 551: 452–458Google Scholar
  21. Caine E, Kartzinel R, Ebert M, Carter AC (1978) Neuroendocrine function in Huntington’s disease: dopaminergic regulation of prolactin release. Life Sci 22: 911–918PubMedCrossRefGoogle Scholar
  22. Caraceni TA, Panerai AE, Parati EA, Cocchi D, Muller EE (1977) Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington’s chorea. J Clin Endocrinol Metab 44: 870–875PubMedCrossRefGoogle Scholar
  23. Caraceni TA, Parati EA, Cocchi D, Mainini P, Muller EE (1979) Neuroendocrine correlates in Huntington’s chorea. In: Muller EE, Agnoli A (eds) Neuroendocrine correlates in neurology and psychiatry. Elsevier, Amsterdam, pp 167–178Google Scholar
  24. Cassiman JJ, Verlinden J, Vlietinck RF, Bellemans J, Van Leuven F, Deroover J, Baro F, Van Den Berghe H (1979). The qualitative and quantitative study of the growth and cell surface properties of Huntington’s disease fibroblasts and age matched controls. Hum Genet 1: 75–86CrossRefGoogle Scholar
  25. Chalmers RJ, Johnson RH, Keogh HJ, Nanda RN (1978) Growth hormone and prolactin response to 174 bromocryptine in patients with Huntington’s chorea. J Neurol Neurosurg Psychiatry 41: 135–139PubMedCrossRefGoogle Scholar
  26. Chandler JH (1969) EEG in the prediction of Huntington’s chorea. In: Barbeau A, Brunette JR (eds) Progress in neurogenetics, Vol I. Excerpta Medica, Amsterdam, pp 564–585Google Scholar
  27. Comings DE (1979) A search for the mutant protein in Huntington’s disease and schizophrenia. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 335–349Google Scholar
  28. Crow TJ, Johnstone EC, Owens DG, Ferrier IN, MacMillan JF, Perry RP, Tyrell DA (1979) Lancet I: 842–S44Google Scholar
  29. Curtis DR (1976) Some aspects of the clinical neuropharmacology of amino acid neurotransmitters.In: Yahr MD (ed) The basal ganglia. Raven Press, New York, pp 163–183Google Scholar
  30. Curzon G, Gumpert J, Sharpe D (1972) Amine metabolites in the cerebrospinal fluid in Huntington’s chorea. J Neurol Neurosurg Psychiatry 35: 514–519PubMedCrossRefGoogle Scholar
  31. Diamond BI, Borison RL (1978) Enkephalins and nigrostriatal function. Neurology (Minneap) 28: 1085–1088Google Scholar
  32. Diamond BI, Comaty JE, Sudakoff GS, Haudata HS, Walter R, Borison RL (1979) Role of substance P as a ‘transducer’ for dopamine in model choreas. In: Chase TN, Wexler N, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 505–515Google Scholar
  33. Emson PC, Rehfeld JF, Langevin H, Rossar R (1980) Reduction in cholecystokinin-like immunoreactivity in the basal ganglia in Huntington’s disease. Brain Res 198: 497–500PubMedCrossRefGoogle Scholar
  34. Enna SJ, Bird ED, Bennett JP, Bylund DB, Yamamura HI, Iversen LL, Snyder SN (1976) Huntington’s chorea: changes in neurotransmitter receptors in the brain. N Engl J Med 294: 1305–1309PubMedCrossRefGoogle Scholar
  35. Enna SJ, Stern LZ, Wastek GJ, Yamamura HI (1977) Cerebrospinal fluid and gamma-aminobutyric acid variations in neurological disorders. Arch Neurol 34: 683–685PubMedGoogle Scholar
  36. Foerster K, Freudenberg J (1980) HLA antigen frequencies in patients with Huntington’s chorea and their relatives. J Neurol 223: 119–125PubMedCrossRefGoogle Scholar
  37. Frattola L, Albizzati MG, Bassi S, Trabucchi M (1979) Plasma prolactin levels: control by dopamine and GABA in Huntington’s chorea patients. In: Muller EG, Agnoli A (eds) Neuroendocrine correlates in neurology and psychiatry. Elsevier/North-Holland, Amsterdam, pp 159–162Google Scholar
  38. Frederickson DS, Goldstein JL, Brown MS (1978) The familial hyperlipoproteinemias. In: Stanbury JB, Wyngaarden JB, Frederickson DS (eds) The metabolic basis of inherited disease, 4th edn. McGraw-Hill, New York, pp 604–655Google Scholar
  39. Gajdusek C (1977) Report of the Commission for the Control of Huntington’s Disease and its Consequences, vol II, Technical report. US Government Printing Office, Washington, DC, p 20Google Scholar
  40. Glaeser BS, Vogel WH, Oleweiler DB, Hare TA (1975) GABA levels in cerebrospinal fluid of patients with Huntington’s chorea: a preliminary report. Biochem Med 12: 380–385PubMedCrossRefGoogle Scholar
  41. Goetz J, Roberts E, Comings ED (1975) Fibroblasts in Huntington’s disease. N Engl J Med 293: 1225–1227PubMedCrossRefGoogle Scholar
  42. Goetz I, Roberts E, Warren J, Comings DE (1979) Growth of Huntington’s disease fibroblasts during their in vitro life span. In: Chase TN, Wexler N, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 351–359Google Scholar
  43. Goodman RM, Hall CL, Terango L, Perrine GA, Roberts PL (1966) Huntington’s chorea: a multidisciplinary study of affected parents and first generation offspring. Arch Neurol 15: 345–355PubMedGoogle Scholar
  44. Gray PN, Dana SL (1979) GABA synthesis by cultured fibroblasts obtained from persons with Huntington’s disease. J Neurochem 33: 985–992PubMedCrossRefGoogle Scholar
  45. Harper RA, Grove G (1979) Human skin fibroblasts derived from papillary and reticular dermis: differences in growth potential in vitro. Science 204: 526–527PubMedCrossRefGoogle Scholar
  46. Hayden, MR (1979) Communication to Eighth International Workshop on Huntington’s Chorea, Oxford, EnglandGoogle Scholar
  47. Hayden MR, Vinik AI (1979) Disturbances in hypothalamic-pituitary hormonal dopaminergic regulation in Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 305–315Google Scholar
  48. Hayden MR, Vinik AI, Paul M, Beighton P (1977) Impaired prolactin release in Huntington’s chorea: evidence for dopaminergic excess. Lancet II: 423–426PubMedCrossRefGoogle Scholar
  49. Hiley CR, Bird ED (1974) Decreased muscarinic receptor concentration in post mortem brain in Huntington’s chorea. Brain Res 80: 355–358PubMedCrossRefGoogle Scholar
  50. Husby G, Li L, Davis LE (1977) Antibodies to human caudate nucleus neurons in Huntington’ chorea. J Clin Invest 59: 922–932PubMedCrossRefGoogle Scholar
  51. Husby G, Forre O, Williams RC (1979) IgG subclass variable H-chain subgroup and light chain-type composition of antineuronal antibody in Huntington’s disease and Sydenham’s chorea. Clin Immunol Immunopathol 14: 361–367PubMedCrossRefGoogle Scholar
  52. Igbal K, Tellez-Nagel I, Grundke-Igbal I (1974) Protein abnormalities in Huntington’s chorea. Brain Res 76: 178–184CrossRefGoogle Scholar
  53. Johnson EW, Radecki PL, Paulson GW (1977) Huntington’s disease: early identification by H-reflex 175 testing. Arch Phys Med Rehabil 58: 162–166PubMedGoogle Scholar
  54. Kanazawa I, Bird ED, O’Connell R, Powell D (1977) Evidence for a decrease in substance P content of substantia nigra in Huntington’s chorea. Brain Res 120: 387–392PubMedCrossRefGoogle Scholar
  55. Kanazawa I, Bird ED, Gale JS, Iversen LL, Jessell TM, Muramoto O, Spokes EG, Sutoo D (1979) Substance P: decrease in substantia nigra and globus pallidus in Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 495–504Google Scholar
  56. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  57. Keogh HJ, Johnson RH, Nanda RN, Sulaiman WR (1976) Altered growth hormone release in Huntington’s chorea. J Neurol Neurosurg Psychiatry 39: 244–248PubMedCrossRefGoogle Scholar
  58. Kirk D, Parrington JM, Corney G, Bolt JMW (1977) Anomalous cellular proliferation in vitro associated with Huntington’s disease. Hum Genet 30: 143–154CrossRefGoogle Scholar
  59. Kjellin KG, Stibler H (1974) CSF-protein patterns in extra-pyramidal diseases: preliminary report with special reference to the protein patterns in Huntington’s chorea. Eur Neurol 12: 186–194PubMedCrossRefGoogle Scholar
  60. Klawans H, Goetz CG, Paulson GW, Barbeau A (1980) Levadopa and presymptomatic detection of Huntington’s disease: eight-year follow up (letter) N Engl J Med 302: 1090PubMedCrossRefGoogle Scholar
  61. Klawans HL, Paulson GW, Ringel SP, Barbeau A (1972) Use of L-dopa in the detection of presymptomatic Huntington’s chorea. N Engl J Med 286: 1332–1334PubMedCrossRefGoogle Scholar
  62. Leonardi A, De Martini IS, Perdelli F, Mancardi GL, Salvarani S, Bugiani O (1978) Skin fibroblasts in Huntington’s disease. N Engl J Med 298: 632PubMedGoogle Scholar
  63. Leopold NA, Podolsky S (1979) Levodopa and glucose influence on prolactin secretion in Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 299–304Google Scholar
  64. Lloyd KG, Dreksler ED, Bird ED (1977) Alterations in 3H-GABA binding in Huntington’s chorea. Life Sci 21: 747–754PubMedCrossRefGoogle Scholar
  65. Lloyd KG, Davidson L (1979) Alterations in 3H-GABA binding in Huntington’s disease: a phospholipid component? In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 705–715Google Scholar
  66. Lyle OE, Gottesman II (1977) Premorbid psychometric indicators of the gene for Huntington’s disease. J Consult Clin Psychol 45: 1011–1022PubMedCrossRefGoogle Scholar
  67. Lyle OE, Gottesman II (1979) Subtle cognitive deficits as 15 to 20 year precursors of Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 227–238Google Scholar
  68. McGeer PL, McGeer EG, Fibiger HC (1973) Choline acetylase and glutamic acid decarboxylase in Huntington’s chorea. Neurology (Minneap) 23: 912–917Google Scholar
  69. McGeer PL, McGeer EG, Scherer U, Singh H (1977) A glutaminergic corticostriatal pathway? Brain Res 128: 369–373PubMedCrossRefGoogle Scholar
  70. McGeer EG, McGeer PL, Hattori T, Vincent SR (1979) Kainic acid neurotoxicity and Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 577–591Google Scholar
  71. McHenemey WH (1961) Immunity mechanisms in neurological disease. Proc R Soc Med 54: 127–136Google Scholar
  72. McKusick VA (1978) Mendelian inheritance in man: catalogue of autosomal dominant, recessive and X-linked phenotypes, 5th edn. Johns Hopkins University Press, BaltimoreGoogle Scholar
  73. Magnusson T, Carllson A, Fisher GH, Chang D, Folkers K (1976) Effect of synthetic substance P on monoaminergic mechanisms in brain. J Neurol Transm 38: 89–93CrossRefGoogle Scholar
  74. Manyam NV, Hare TA, Katz L, Glaeser BS (1978) Huntington’s disease: cerebrospinal fluid GABA levels in at-risk individuals. Arch Neurol 35: 728–730PubMedGoogle Scholar
  75. Markesberry WR, Butterfield DA (1977) Scanning electron microscopy studies of erythrocytes in Huntington’s disease. Biochem Biophys Res Commun 78: 560–564CrossRefGoogle Scholar
  76. Marsden CD (1979) Animal models of Huntington’s disease: a review. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 567–576Google Scholar
  77. Mattsson B (1974) Clinical, genetic and pharmacological studies in Huntington’s chorea. UMEA University Medical Dissertations 7. UMEA, Sweden, pp 21–51Google Scholar
  78. Menkes JH, Stein N (1973) Fibroblast cultures in Huntington’s disease (letter). N Engl J Med 288: 856–857PubMedGoogle Scholar
  79. Morrell RM (1979) Antibody-dependent cytoxicity in Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 443–447Google Scholar
  80. Moshell AN, Barrett SF, Tarone RE, Robbins JH (1980) Radiosensitivity in Huntington’s disease: implications for pathogenesis and presymptomatic diagnosis. Lancet I: 9–11Google Scholar
  81. Muller EE, Parati EA, Cocchi D, Zanardi P, Caraceni T (1979) Dopaminergic drugs on growth hormone and prolactin secretion in Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 319–334Google Scholar
  82. Myers RH, Falek A (1979) Quantification of muscle tremor of Huntington’s disease patients and their offspring in an early detection study. Biol Psychiatry 14: 777–789PubMedGoogle Scholar
  83. Neophytides AN, Di Chiro G, Barron SA, Chase TN (1979) Computer axial tomography in Huntington’s disease and persons at-risk for Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 185–191Google Scholar
  84. Noronha AB, Roos RP, Antel JP, Arnason BG (1979) Huntington’s disease: abnormality of lymphocyte capping. Ann Neurol 6: 447–450 Olney JW (1979) Excitotoxic amino acids and Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 609–624Google Scholar
  85. Olney JW, De Gubareff T (1978) The fate of synaptic receptors in the kainate-lesioned striatum. Brain Res 140: 340–343PubMedCrossRefGoogle Scholar
  86. Olsen RW, Van Ness P, Tourtellotte WW (1979) Gamma-aminobutyric acid receptor binding curves for human brain regions: comparison of Huntington’s disease and normal. In Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 697–704Google Scholar
  87. Palm JD (1973) Longitudinal study of a preclinical test program for Huntington’s chorea. In: Barbeau A, Chase TN, Paulson GW (eds) Huntington’s chorea, 1872–1972. Raven Press, New York, pp 311–325Google Scholar
  88. Patterson RM, Bagchi BK, Test A (1948) Prediction of Huntington’s chorea: an electroencephalographic and genetic study. Am J Psychiatry 104: 786–797PubMedGoogle Scholar
  89. Paulson GW (1979) Diagnosis of Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 177–184Google Scholar
  90. Pericak-Vance MA, Conneally PM, Merritt AD, Roos RP, Vance JM, Yu PL, Norton JA, Antel JP (1979) Genetic linkage in Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 59–72Google Scholar
  91. Perry T (1979) Communication to Eighth International Workshop on Huntington’s Chorea, Oxford, England Perry TL, Hansen S, Klosker M (1973) Huntington’s chorea: deficiency of gamma-aminobutyric acid in brain. N Engl J Med 288: 337–342PubMedCrossRefGoogle Scholar
  92. Perry TL, Kish S, Hansen S, Buchanan J (1978) Brain gamma-aminobutyric acid deficiency in schizophrenia and Huntington’s chorea. In: Proceedings of the Second International Symposium on Huntington’s Disease, p A65Google Scholar
  93. Petit H (1979) Communication to Eighth International Workshop on Huntington’s chorea, Oxford, EnglandGoogle Scholar
  94. Petit H, Milbled G (1973) Anomalies of conjugate ocular movements in Huntington’s chorea: application to early detection. In: Barbeau A, Chase TN, Paulson GW (eds) Huntington’s chorea, 1872–1972. Raven Press, New York, pp 287–294Google Scholar
  95. Pettegrew JW, Nichols JS, Stewart RM (1979) Fluorescence spectroscopy on Huntington’s fibroblasts. J Neurochem 33: 905–911PubMedCrossRefGoogle Scholar
  96. Phillipson OT, Bird ED (1976) Plasma growth hormone concentration in Huntington’s chorea. Clin Sci Mol Med 50: 551–554PubMedGoogle Scholar
  97. Podolsky S, Leopold NA (1974) Growth hormone abnormalities in Huntington’s chorea: effect of L-dopa administration. J Clin Endocrinol Metab 39: 36–39PubMedCrossRefGoogle Scholar
  98. Reisine TD, Fields JZ, Bird ED, Spokes E, Yamamura HI (1978) Characterisation of brain dopaminergic receptors in Huntington’s disease. Comm Psychopharmacol 2: 79–84Google Scholar
  99. Reisine TD, Beaumont K, Bird ED, Spokes E, Yamamura HI (1979) Huntington’s disease: alterations in neuro-transmitter receptor binding in the human brain. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 717–726Google Scholar
  100. Ringel SP, Weiner WJ, Rubovitz R, Klawans HL (1973) Methysergide in Huntington’s chorea. In: Barbeau A, Chase TN, Paulson GW (eds) Huntington’s chorea, 1872–1972. Raven Press, New York, pp 769–776Google Scholar
  101. Roth RH, Ando N, Simon JR, Bird ED, Gold BI (1979) Gamma-hydroxybutyrate: alterations in endogenous brain levels in Huntington’s disease. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 557–566Google Scholar
  102. Sanberg PR, Fibiger HC (1979) Body weight, feeding and drinking behaviours in rats with kainic acid- induced lesions of striatal neurones. Exp Neurol 66: 444–446PubMedCrossRefGoogle Scholar
  103. Schneider EL (1979) Cell replication and aging: in vitro and in vivo studies. Fed Proc 38: 1857–1861PubMedGoogle Scholar
  104. Spokes EG (1979) Dopamine in Huntington’s disease: a study of postmortem brain tissue. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 481–493Google Scholar
  105. Spokes EG (1980) Neurochemical alterations in Huntington’s chorea: a study of postmortem brain tissue. Brain 103: 179–210PubMedCrossRefGoogle Scholar
  106. Tamminga C, Neophytides A, Chase TN, Frohman LA (1979) Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. J Clin Endocrinol Metab 47: 1348–1351CrossRefGoogle Scholar
  107. Tourian A, Hung W (1977a) Glucosamine dependence of Huntington’s chorea fibroblasts in culture. BBRC 76: 345–353Google Scholar
  108. Tourian A, Hung W (1977b) Membrane abnormalities of Huntington’s chorea fibroblasts in culture. BBRC 78: 1296–1303Google Scholar
  109. Tourian A, Hung W (1979) Huntington’s disease fibroblasts: nutritional and protein glycosylation studies. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 371–386Google Scholar
  110. Valentine WN, Pagilia DC, Tartaglia AP, Gilsanz F (1977) Hereditary hemolytic anemia with increased Current Trends in Research red cell adenosine deaminase and decreased adenosine triphosphate. Science 195: 783–784PubMedCrossRefGoogle Scholar
  111. Wastek GJ, Stern LZ, Johnson PC, Yamamura HI (1976) Huntington’s disease: regional alteration in muscarinic cholinergic receptor binding in human brain. Life Sci 19: 1033–1040PubMedCrossRefGoogle Scholar
  112. Weiner WJ, Hitri A, Carvey P, Roller WC, Nausieda PA, Klawans HL (1979) 3H-dopamine binding studies in guinea pig striatal membrane suggesting two distinct dopamine receptor sites. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 687–695Google Scholar
  113. Went LN, Volkers WS (1979) Genetic linkage. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 37–42Google Scholar
  114. Wu JY, Bird ED, Chen MS, Huang WM (1979) Studies of neurotransmitter enzymes in Huntington’s chorea. In: Chase TN, Wexler NS, Barbeau A (eds) Advances in neurology, vol 23. Raven Press, New York, pp 527–536Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • Michael R. Hayden
    • 1
  1. 1.Division of Clinical GeneticsChildren’s Hospital Medical CenterBostonUSA

Personalised recommendations